Ipamorelin (2mg x 10 Vials) + Mod GRF 1 29 (CJC 1295 no DAC) (2mg x 10 Vials)
Misc (Generics)
Research PeptidesGrowth Hormone Releasing Peptide Combination
Certifications
- Marketed as a research Use Only peptide reagent; not authorised as a medicinal product or as a medical device.
- End users are responsible for ensuring use complies with local research, safety, and import regulations.
- Marketed as a research Use Only peptide reagent; not authorised as a medicinal product or as a medical device.
- End users are responsible for ensuring use complies with local research, safety, and import regulations.
Growth Hormone Releasing Peptide Combination
Description
Peptide Combination Special containing two separate lyophilised peptide preparations: Ipamorelin (2 mg per vial, 10 vials) and Mod GRF 1-29, also known as CJC-1295 without DAC (2 mg per vial, 10 vials). Both peptides are supplied as sterile lyophilised powders intended strictly for laboratory research use. Ipamorelin is a synthetic pentapeptide growth hormone secretagogue receptor agonist (GHS-R/ghrelin receptor), while Mod GRF 1-29 is a tetrasubstituted analogue of growth hormone–releasing hormone (GHRH). The combination is commonly studied in experimental models for potential synergistic effects on pulsatile growth hormone release.
Bnefits
- Combination package provides two complementary research peptides in separate vials: Ipamorelin and Mod GRF 1-29 (CJC-1295 no DAC)
- Each peptide supplied at 2 mg per vial in sets of 10 vials (total 20 vials) for flexible laboratory dosing and protocol design
- Lyophilised (freeze-dried) form supports improved peptide stability during shipping and storage when appropriately handled
- Ipamorelin is a selective growth hormone secretagogue receptor agonist used in experimental GH-release models
- Mod GRF 1-29 (CJC-1295 no DAC) is a GHRH analogue with substitutions designed to improve stability versus native GRF 1-29 in research settings
- Combination is frequently investigated for potential synergistic effects on growth hormone pulses and related endocrine pathways
- Sold and labelled as a research reagent only, not as a medicinal product or dietary supplement
Indications
- Laboratory research use only (e.g., in vitro assays and approved in vivo experimental models studying growth hormone–related signalling)
- Experimental investigation of ghrelin receptor (GHS-R) agonists such as Ipamorelin
- Research on growth hormone–releasing hormone analogues such as Mod GRF 1-29 (CJC-1295 no DAC)
- Study of combined GHRH analogue and GHS-R agonist administration on GH secretion and downstream biological effects in research models
Composition
- Ipamorelin: 2 mg lyophilised peptide powder per vial (10 vials)
- Mod GRF 1-29 (CJC-1295 no DAC): 2 mg lyophilised peptide powder per vial (10 vials)
- Excipients: not specified; typically includes buffering agents and stabilisers appropriate for lyophilised peptide formulations
Formulation
- Sterile lyophilised (freeze-dried) peptide powders in sealed glass vials
- Ipamorelin peptide (synthetic pentapeptide growth hormone secretagogue receptor agonist)
- Mod GRF 1-29 peptide (tetrasubstituted 29–amino acid fragment analogue of growth hormone–releasing hormone)
- Supplied without diluent; requires reconstitution with a suitable sterile solvent prior to experimental use
Packaging
- 10 x 2 mg Ipamorelin lyophilised peptide vials
- 10 x 2 mg Mod GRF 1-29 (CJC-1295 no DAC) lyophilised peptide vials
- Total 20 vials packaged together as a combination research peptide set
Usage
- For laboratory research use only; not for human or veterinary use, diagnostic use, or consumption.
- Handle only by suitably trained laboratory personnel in an appropriate research facility, following institutional safety procedures.
- On receipt, inspect vials for integrity of seals and absence of visible damage or contamination before use.
- Reconstitute lyophilised peptide with a suitable sterile solvent (e.g., bacteriostatic water or sterile water for injection) under aseptic conditions, according to internal laboratory SOPs.
- Record reconstitution volume, resulting concentration, date of reconstitution and responsible operator in laboratory documentation.
- Avoid repeated freeze–thaw cycles of reconstituted solutions; prepare aliquots where appropriate to preserve peptide stability.
- Clearly label all working solutions with peptide name, concentration, and storage conditions.
- Dispose of unused material, vials, syringes and consumables as laboratory chemical/biological waste in accordance with local regulations and institutional policies.
- Do not administer to humans or animals and do not repurpose as a drug, cosmetic, or dietary supplement.
Contraindications
- Not for human or veterinary administration under any circumstances.
- Do not use outside of controlled laboratory or research settings.
- Do not handle without appropriate personal protective equipment (e.g., gloves, lab coat, eye protection) where required by institutional policies.
- Avoid handling by individuals who are pregnant, breastfeeding, or who may be particularly susceptible to unknown toxicological effects.
- Do not use if vials show evidence of damage, compromised seals, or visible particulate contamination.
Adverse Effects
- No safety profile has been established for human or animal use; all potential adverse effects in such contexts are unknown and product is not intended for such use.
- Laboratory personnel may experience irritation or sensitisation from accidental contact, inhalation or eye exposure; appropriate PPE and engineering controls should be used.
- Potential but unidentified toxicological, allergenic, endocrine, or carcinogenic effects may exist if mishandled or misused.
Storage Conditions
- Store lyophilised vials in a cool, dry place, protected from direct light.
- Refrigerated storage (approximately 2–8°C) is generally recommended for short- to medium-term storage of lyophilised peptides when consistent with internal SOPs.
- For long-term storage, freezing at lower temperatures (e.g., at or below -20°C) is often recommended to help maintain peptide integrity.
- After reconstitution, store solutions under refrigerated conditions and use within timeframes defined by laboratory stability assessments; avoid repeated freeze–thaw cycles.
- Keep vials tightly closed when not in use and out of reach of unauthorised personnel.
Duration
Not applicable \u2013 this research peptide combination has no authorised therapeutic regimen or treatment schedule.
Onset
Not applicable \u2013 pharmacodynamic onset and clinical effects in humans are not established; product is not approved for therapeutic use.
